Tonix makes two new hires
This article was originally published in Scrip
Executive Summary
Tonix Pharmaceuticals, a US company developing drugs for central nervous system disorders, has appointed Dr Leland Gershell as chief financial officer and Dr Bruce Daugherty in the newly created position as senior director of drug development. Benjamin Selzer, who served as interim chief financial officer, will continue as the company's chief operating officer. Dr Gershell most recently served as managing director and senior analyst at Madison Williams and Company, where he provided research on specialty pharmaceutical and biotechnology companies, while Dr Daugherty has more than 30 years' experience in drug development and scientific research, mostly with Merck & Co, where he most recently served as senior research fellow.
You may also be interested in...
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.